These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15536688)

  • 1. Rash correlates with tumour response after cetuximab.
    Susman E
    Lancet Oncol; 2004 Nov; 5(11):647. PubMed ID: 15536688
    [No Abstract]   [Full Text] [Related]  

  • 2. Rash conclusions from a phase 3 study of cetuximab?
    Harrington KJ
    Lancet Oncol; 2010 Jan; 11(1):2-3. PubMed ID: 20129123
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Crit Rev Oncol Hematol; 2015 Feb; 93(2):127-35. PubMed ID: 25139841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
    Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
    Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nimotuzumab: evidence of clinical benefit without rash.
    Allan DG
    Oncologist; 2005 Oct; 10(9):760-1. PubMed ID: 16249358
    [No Abstract]   [Full Text] [Related]  

  • 6. Is cetuximab-induced rash conclusion really a remnant of the skin erythema dose?
    Oskan F; Belka C; Manapov F
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):462-3. PubMed ID: 24074919
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis.
    Orditura M; De Vita F; Galizia G; Lieto E; Vecchione L; Vitiello F; Martinelli E; Ciardiello F
    Oncol Rep; 2009 Apr; 21(4):1023-8. PubMed ID: 19288004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baboon syndrome induced by cetuximab.
    Sans V; Jouary T; Hubiche T; Smith D; Milpied B; Taieb A
    Arch Dermatol; 2008 Feb; 144(2):272-4. PubMed ID: 18283197
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical issues in the administration of an anti-epidermal growth factor receptor monoclonal antibody, IMC-C225.
    Hollywood E
    Semin Oncol Nurs; 2002 May; 18(2 Suppl 2):30-5. PubMed ID: 12053862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147.
    Jatoi A; Green EM; Rowland KM; Sargent DJ; Alberts SR
    Oncology; 2009; 77(2):120-3. PubMed ID: 19622902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment options for colorectal cancer.
    Erlichman C; Sargent DJ
    N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
    [No Abstract]   [Full Text] [Related]  

  • 12. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.
    Wei F; Shin D; Cai X
    Int J Clin Oncol; 2018 Jun; 23(3):443-451. PubMed ID: 29289981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
    Atherton PJ; Burger KN; Loprinzi CL; Neben Wittich MA; Miller RC; Jatoi A; Sloan JA
    Support Care Cancer; 2012 Aug; 20(8):1729-35. PubMed ID: 21922203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.
    Jatoi A; Nguyen PL
    Oncologist; 2008 Nov; 13(11):1201-4. PubMed ID: 18988655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
    Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
    Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
    Pérez-Soler R
    Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):23-8. PubMed ID: 14682120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody-induced papulopustular rash: Clinical course, communication to health-care professionals and reactive measures as reported by patients.
    Cignola S; Gonella S; Alessandra B; Palese A
    Eur J Oncol Nurs; 2016 Feb; 20():133-9. PubMed ID: 26187661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will cetuximab-induced follicular rash get worse with moisturizers containing liquid paraffinum?
    Manganoni AM; Pavoni L; Calzavara-Pinton P
    Jpn J Clin Oncol; 2014 Jun; 44(6):607-8. PubMed ID: 24755543
    [No Abstract]   [Full Text] [Related]  

  • 20. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
    Gatzemeier U; von Pawel J; Vynnychenko I; Zatloukal P; de Marinis F; Eberhardt WE; Paz-Ares L; Schumacher KM; Goddemeier T; O'Byrne KJ; Pirker R
    Lancet Oncol; 2011 Jan; 12(1):30-7. PubMed ID: 21169060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.